Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Interpace BiosciencesIDXG +2.55%41 Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus rates IDXG with a GF Score™ of 41/100 and a GF Value™ of $0.20 (Significantly Overvalued). The stock has 5 warning signs investors should review. Among 181 Medical Diagnostics & Research companies, Interpace Biosciences ranks better than 88.95% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Interpace Biosciences's Debt-to-Equity or its related term are showing as below:
IDXG'
s Debt-to-Equity Range Over the Past 10 Years
Min: -7.58 Med: -0.22 Max: 5.12
Current: 0.04
During the past 13 years, the highest Debt-to-Equity Ratio of Interpace Biosciences was 5.12. The lowest was -7.58. And the median was -0.22.
IDXG's Debt-to-Equity is ranked better than 88.95% of 181
companies
in the Medical Diagnostics & Research industry
Industry Median: 0.28
vs IDXG: 0.04
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Interpace Biosciences Debt-to-Equity Related Terms
Interpace Biosciences Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Interpace Biosciences's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
IDXG vs PRPO, ADVB, BIOQ: Debt-to-Equity Comparison
For the Diagnostics & Research subindustry, Interpace Biosciences's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Interpace Biosciences Debt-to-Equity vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Interpace Biosciences's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Interpace Biosciences's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Interpace Biosciences (IDXG) has a Debt-to-Equity of 0.04 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Interpace Biosciences and its competitors. According to the industry distribution chart, Interpace Biosciences ranks #20 out of 181 companies in the Medical Diagnostics & Research industry, placing it in the top 11%.
Is Interpace Biosciences' Debt-to-Equity too high?
Interpace Biosciences' current Debt-to-Equity is 0.04. The Medical Diagnostics & Research industry median Debt-to-Equity is 0.28. Interpace Biosciences' value of 0.04 is 85.7% below this industry median. Based on the distribution chart, Interpace Biosciences ranks #20 out of 181 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, Interpace Biosciences has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Interpace Biosciences' Debt-to-Equity compare to PRPO and ADVB?
According to the Medical Diagnostics & Research industry distribution chart, Interpace Biosciences ranks #20 out of 181 companies for Debt-to-Equity. This places Interpace Biosciences in the top 11% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.28. Interpace Biosciences' value of 0.04 is 85.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Medical Diagnostics & Research company?
The median Debt-to-Equity among Medical Diagnostics & Research companies is 0.28, based on 181 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Interpace Biosciences's current Debt-to-Equity of 0.04 is 85.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Interpace Biosciences and its competitors. For the Medical Diagnostics & Research industry, the median Debt-to-Equity is 0.28 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Interpace Biosciences's current Debt-to-Equity is 0.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Interpace Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Interpace Biosciences (IDXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.20, compared to a current price of $1.61 — trading 705% above its estimated fair value. The current Debt-to-Equity is 0.04 and 85.7% below the Medical Diagnostics & Research industry median of 0.28. Interpace Biosciences' overall GF Score™ is 41/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Interpace Biosciences (IDXG), the current Debt-to-Equity is 0.04 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Interpace Biosciences (IDXG) Overvalued in 2026?
Based on GuruFocus' analysis, Interpace Biosciences stock appears to be overvalued.
The current stock price of $1.61 is trading 705% above its estimated GF Value™ of $0.20.
GuruFocus considers Interpace Biosciences to be Significantly Overvalued.
Key valuation signals for IDXG:
Debt-to-Equity: 0.04
GF Value™: $0.20 vs. price of $1.61 (705% above fair value)
Industry Position: 85.7% below the Medical Diagnostics & Research median (#20 of 181)
No single metric tells the full story. See the IDXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Interpace Biosciences Inc provides esoteric molecular diagnostic testing and pathology services to aid physicians in evaluating cancer risk in patients with indeterminate biopsies and a perceived high risk of cancer based on clinical features. The company develops and commercializes genomic tests and related first-line assays that can personalize medicine and help improve patient diagnosis and management. Its clinical customers mainly consist of physicians, hospitals, cancer centers, commercial laboratories, pathology groups, and clinics. The various diagnostic tests offered by the company include ThyGeNEXT and ThyraMIRv2 for the detection of thyroid cancer.
41GF Score
Get the complete analysis for IDXG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IDXG has been successfully added to your 
